An interventional study of smartphone-assisted hybrid cardiac rehabilitation (SHCR) in Heart Failure, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Heart Failure by National Taiwan University Hospital — 7 open to participants now, 9 under way, 1 of them phase 3. Heart Failure · National Taiwan University Hospital.
Among the 25 studies in Heart Failure by National Taiwan University Hospital, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 10 with no phase, and was the 15th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →7 of the 25 studies in Heart Failure by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+
National Taiwan University Hospital
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 60 across the 15 interventional studies, 150 across the 10 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
1 of the studies in Heart Failure by National Taiwan University Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06892652National Taiwan University HospitalComprehensive Management for Terminal Heart Failure Program: | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Heart Failure by National Taiwan University Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this randomized controlled trial is to compare the impact of a case manager-led smartphone-assisted hybrid cardiac rehabilitation program with usual care in patients with HF. Participants will undergo a 12-week program led by a case manager and assisted by a smartphone. The study aims to answer two main questions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a 12-wk case manager-led smartphone-assisted hybrid cardiac rehabilitation with follow-up at 12 week and 6 months.
Other: smartphone-assisted hybrid cardiac rehabilitation (SHCR)
Participants receive usual care including general education and exercise suggestion.
The 12-week case manager-led SHCR program includes: * Customized exercise prescriptions following ACSM's heart failure guidelines. * A hybrid program combining in-person sessions, home self-exercise, and videoconferencing for exercise coaching(optional), supported by a smartphone app. * Case managers instruct patients on a communication app for weekly follow-ups, health education messages, exercise reminders, and progress tracking, including metrics like blood pressure, heart rate, weight, and symptoms.
Change of peak oxygen uptake
Peak oxygen uptake will be assessed using cardiopulmonary exercise test before intervention, at 12 weeks (post-intervention), and at 6 months.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Change of 6 minute walking test
6 minute walking test will be performed before intervention, at 12 weeks (post-intervention), and at 6 months.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Adherence to prescribed exercise
We will evaluate the percentage of completed prescribed exercises at 12 weeks.
Time frame: 12 weeks(post-intervention)
Evaluation of Quality of life
The investigators will assess the change in 36-Item Short Form Survey(SF-36).
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Depression
The investigators will assess the change in Patient Health Questionnaire (PHQ-9). The PHQ-9 score ranges from 0-27. Higher scores indicate worsen symptoms.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Anxiety
The investigators will assess the change in Generalized Anxiety Disorder scale (GAD-7). The GAD-7 score ranges 0-21. Higher scores indicate worsen symptoms.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Evaluation of physical activity
The investigators will assess the change in physical activity using International Physical Activity Questionnaire(IPAQ) Taiwan version.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Evaluation of grip strength
The grip strength will be measured using a grip goniometer with the participants seated and the elbow flexed at 90 degrees.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Evaluation of frailty
The investigators will evaluate the change in the Clinical Frailty Scale, which ranges from 1 to 9. Higher scores represent greater illness.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: Total cholesterol
The Total cholesterol will be tested in the laboratory.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: LDL
The LDL will be tested in the laboratory.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: HDL
The HDL will be tested in the laboratory.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: Triglyceride
The Triglyceride will be tested in the laboratory.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: NT-proBNP
The NT-proBNP will be tested in the laboratory.
Time frame: at baseline, 12 weeks(post-intervention), and 6 months.
Started Jan 2024 (actual). Primary completion is estimated for Dec 2028, 58 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 58 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital →